FLEXISEQ Gel Launched in UK - Pioneering joint pain treatment supports leading Arthritis charity
London, United Kingdom (PRWEB UK) 3 December 2013 FLEXISEQ's proven efficacy comes with significant advantages as the product has no contra-indications, contains no drugs so cannot cause drug-to-drug interactions, and with over 6 million doses administered since launch there have been no reported systemic side effects. FLEXISEQ is already successfully sold in the early pilot markets of Austria, Germany, Ireland, Malaysia and Singapore. Earlier this year, FLEXISEQ won the Innovation Award 2013 from the Federal Association of German Pharmacists. In June, FLEXISEQ launched in Ireland and became the fastest growing over-the-counter product that pharmacies there had seen in recent times. UK Charity Launch John Mayo, Chairman and Chief Executive of Pro Bono Bio said "I am proud to bring the world's first clinically proven nano-physical product for pain relief to the UK. For the UK Charity launch period, FLEXISEQ is exclusively available online via the Arthritis Research UK websi...